keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer and quality of life

keyword
https://www.readbyqxmd.com/read/29777382/mood-sexuality-and-relational-intimacy-after-starting-androgen-deprivation-therapy-implications-for-couples
#1
Lauren M Walker, Pablo Santos-Iglesias, John Robinson
BACKGROUND: Patients on androgen deprivation therapy (ADT), a common treatment for prostate cancer, report significant declines in quality of life and detrimental impact on their intimate relationships. ADT depresses a man's testosterone to castrate levels, leading to declines in sexual function, and changes in mood. These changes can have profound impact on couples' intimate relationships. METHOD: Patients undergoing ADT, and their consenting partners, were followed on a variety of outcomes relating to mood, sexual changes, and relational intimacy...
May 18, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29774804/patient-preferences-and-urologist-judgments-on-prostate-cancer-therapy-in-japan
#2
Masahiko Nakayama, Hisanori Kobayashi, Masateru Okazaki, Keiichiro Imanaka, Kazutake Yoshizawa, Jörg Mahlich
The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute...
May 1, 2018: American Journal of Men's Health
https://www.readbyqxmd.com/read/29770953/a-systematic-review-of-physical-activity-based-behaviour-change-interventions-reaching-men-with-prostate-cancer
#3
REVIEW
A Finlay, G Wittert, C E Short
PURPOSE: Men who are survivors of prostate cancer report a variety of psychological and physical factors contributing to a lower quality of life, and physical activity can assist to mitigate these issues. This review aims to provide a summary of physical activity behaviour change trials targeting prostate cancer survivors, assess the feasibility of these interventions and, if possible, identify intervention and study characteristics associated with significant intervention effects. METHOD: Four databases (PubMed, CINAHL, PsycINFO and EMBASE) were systematically searched for randomised controlled trials containing at least one behavioural outcome relating to physical activity published up until July 2016...
May 16, 2018: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29769060/biopro-rcmi-1505-trial-multicenter-study-evaluating-the-use-of-a-biodegradable-balloon-for-the-treatment-of-intermediate-risk-prostate-cancer-by-intensity-modulated-radiotherapy-study-protocol
#4
David Pasquier, Emilie Bogart, François Bonodeau, Thomas Lacornerie, Eric Lartigau, Igor Latorzeff
BACKGROUND: Prospective trials have demonstrated the advantage of dose-escalated radiotherapy for the biochemical and clinical control of intermediate risk prostate cancer. Dose escalation improves outcomes but increases risks of urinary and bowel toxicity. Recently the contribution of "spacers" positioned in the septum between the rectum and the prostate could improve the functional results of intensity modulated radiation therapy (IMRT). To date most of the evaluated devices were polyethylen glycol (PEG) and hyaluronic acid (HA)...
May 16, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29764892/intense-exercise-for-survival-among-men-with-metastatic-castrate-resistant-prostate-cancer-interval-gap4-a-multicentre-randomised-controlled-phase-iii-study-protocol
#5
Robert U Newton, Stacey A Kenfield, Nicolas H Hart, June M Chan, Kerry S Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A Galvão, Charles J Ryan, Fred Saad
INTRODUCTION: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS AND ANALYSIS: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC)...
May 14, 2018: BMJ Open
https://www.readbyqxmd.com/read/29764181/symptom-clusters-using-the-eortc-qlq-c15-pal-in-palliative-radiotherapy
#6
Vithusha Ganesh, Liying Zhang, Bo Angela Wan, Leah Drost, May Tsao, Elizabeth Barnes, Carlo DeAngelis, Hans Chung, Patrick Diaz, Edward Chow
BACKGROUND: Patients with advanced cancer often experience a multitude of symptoms. Due to the potential interrelation of symptoms, symptom clusters of 2 or more concurrent symptoms have been advocated for use in the palliative setting to provide better management of symptoms. METHODS: The principal component analysis (PCA), exploratory factor analysis (EFA) and hierarchal cluster analysis (HCA) were conducted on responses to items 1-14 in the European Organisation for Research and Treatment of Cancer Quality of Life-C15-Palliative (EORTC QLQ-C15-PAL) at baseline and days 5 and 10 following RT...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29755791/local-treatment-of-metastatic-prostate-cancer-what-is-the-evidence-so-far
#7
REVIEW
Pedro Leonel Almeida, Bruno Jorge Pereira
Background: Advances in technological, laboratorial, and imaging studies and new treatments available in the last decades significantly improved prostate cancer survival rates. However, this did not occur in metastatic prostate cancer (mPCa) at diagnosis which, in young and fit patients, will become invariably resistant to the established treatments. Progression will lead to an impairment in patients' quality of life and disease-related death. Methods: The authors intend to perform a literature review of the advantages of primary treatment of mPCa...
2018: Prostate Cancer
https://www.readbyqxmd.com/read/29753523/testicular-transposition-in-children-undergoing-brachytherapy-for-bladder-and-or-prostate-rhabdomyosarcoma
#8
Guenolee de Lambert, Cyrus Chargari, Véronique Minard-Colin, Christine Haie-Meder, Florent Guérin, Hélène Martelli
BACKGROUND/PURPOSE: Fertility preservation is a major goal in treatment of children with cancer. We describe a new technique of testicular transposition (TT) in patients treated with pulse-dose-rate (PDR) brachytherapy as part of the multimodal conservative treatment of bladder neck and/or prostate rhabdomyosarcoma (BP RMS). METHODS: Medical records of consecutive patients treated between September 2016 and August 2017 were studied. These patients underwent a TT performed during BP RMS surgery by the same suprapubic incision...
April 13, 2018: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#9
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29752141/predictors-of-falls-in-older-survivors-of-breast-and-prostate-cancer-a-retrospective-cohort-study-of-surveillance-epidemiology-and-end-results-medicare-health-outcomes-survey-linkage
#10
Min H Huang, Jennifer Blackwood, Monica Godoshian, Lucinda Pfalzer
OBJECTIVES: To identify predictors of falls in older breast and prostate cancer survivors. METHODS: This retrospective cohort study analyzed population-based Surveillance, Epidemiology and End Results-Medicare Health Outcomes Survey (SEER-MHOS) linkage. Inclusion criteria were age >65 years at cancer diagnosis, first primary female breast or prostate cancer, cancer staging information available, completion of baseline MHOS during years 2-3 and follow-up MHOS during years 4-5 post-diagnosis, and falls information available...
May 8, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29750398/body-composition-fatigue-and-exercise-in-patients-with-prostate-cancer-undergoing-androgen-deprivation-therapy
#11
Robert U Newton, Emily Jeffery, Daniel A Galvão, Carolyn McIntyre, Nigel Spry, David Joseph, Jim Denham, Dennis R Taaffe
OBJECTIVES: To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and following exercise in patients with prostate cancer already undergoing androgen deprivation therapy (ADT). SUBJECTS AND METHODS: Cross-sectional associations between lean and fat mass with fatigue and/or vitality measures were examined in 229 patients (43-90 years). Prospective analysis was undertaken in 129 patients who underwent 3-6 months exercise (predominantly resistance + aerobic)...
May 11, 2018: BJU International
https://www.readbyqxmd.com/read/29748830/-give-me-five-ultra-hypofractionated-radiotherapy-for-localized-prostate-cancer-non-invasive-ablative-approach
#12
Giulia Marvaso, Giulia Riva, Delia Ciardo, Sara Gandini, Cristiana Fodor, Dario Zerini, Sarah Pia Colangione, Giorgia Timon, Stefania Comi, Raffaella Cambria, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
Ultra-hypofractionated radiotherapy (RT) is given over a shorter time with larger doses with respect to conventional fractionation in patients with localized prostate cancer (PCa). The use of hypofractionation is supported both from the radiobiological point of view (the low α/β-ratio in PCa and dose escalation) and from the rising number of clinical evidences. The aim of this study is to review our data regarding oncological outcomes, namely biochemical progression-free survival (b-PFS) and clinical progression-free survival (c-PFS), acute and long-term toxicities in patients treated with a ultra-hypofractionated RT...
May 10, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29747490/health-related-quality-of-life-perceived-social-support-and-depression-in-disease-free-survivors-who-underwent-curative-surgery-only-for-prostate-kidney-and-bladder-cancer-comparison-among-survivors-and-with-the-general-population
#13
Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
Purpose: The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population. Materials and Methods: Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9...
May 4, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29741118/15-years-survey-of-safety-and-efficacy-of-serenoa-repens-extract-in-benign-prostatic-hyperplasia-patients-with-risk-of-progression
#14
Andrey Zinovievich Vinarov, Leonid Grigorievich Spivak, Darina Vladimirovna Platonova, Leonid Mikhailovich Rapoport, Dmitry Olegovich Korolev
AIM: The aim of this study is to investigate the efficacy and safety of long-term therapy with Serenoa repens extract with regard to halting benign prostatic hyperplasia progression. MATERIAL AND METHODS: An open non-comparative observational study of the continuous use of S. repens plant extract at a dosage of 320 mg once a day for 15 years was performed in 30 patients at risk for benign prostatic hyperplasia progression. Changes in IPSS (International Prostatic Symptoms Scale) and QoL (Quality of life) scores and changes in Qmax, voided volume, residual urine volume, and prostate volume were evaluated during the study...
May 1, 2018: Urologia
https://www.readbyqxmd.com/read/29738056/-survival-increases-for-all-cancer-diagnoses-but-inequality-persists
#15
Roger Henriksson, Jacob Järås, Kjell Bergfeldt, Lena Sharp, Mona Ridderheim, Eskil Degsell, Thomas Kunze
New data show a continuously increased five-year survival for almost all analyzed cancer diagnoses since 1990. It has to be emphasized that the figures are uncertain due to the limited number of patients. The variation is huge and the greatest improvements are seen not least among the three major tumor diseases (breast, colorectal and prostate cancer), where the society, industry and research bodies made the biggest investments over the years. The causes of improved survival can be sought in several areas, such as earlier detection and better treatments...
May 8, 2018: Läkartidningen
https://www.readbyqxmd.com/read/29732277/health-state-utilities-among-contemporary-prostate-cancer-patients-on-active-surveillance
#16
Stacy Loeb, Caitlin Curnyn, Dawn Walter, Angela Fagerlin, Uwe Siebert, Nick Mühlberger, R Scott Braithwaite, Mark D Schwartz, Herbert Lepor, Erica Sedlander
Background: Active surveillance (AS) is the most rapidly expanding management option for favorable-risk prostate cancer (PCa). Early studies suggested substantial decrements in utility (quality of life weights) from disease-related anxiety. Our objective was to determine utilities for contemporary AS patients using different instruments. Methods: We performed a systematic review of PubMed, PMC and OVID for utility measurements in modern AS patients. We then examined utilities among 37 men on AS participating in focus groups between 2015-2016 using the generic EurQol five dimensions questionnaire (EQ-5D-3L) and Patient Oriented Prostate Utility Scale (PORPUS), a PCa-specific instrument...
April 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29732206/patient-experience-after-transperineal-template-prostate-biopsy-compared-to-prior-transrectal-ultrasound-guided-prostate-biopsy
#17
Nikita R Bhatt, Kieran Breen, Usman M Haroon, Muhammad Akram, Hugh D Flood, Subhasis K Giri
Introduction: Transperineal template prostate biopsy (TTPB) is reported to have higher cancer detection and lower complication rate compared to transrectal ultrasound guided prostate biopsy (TRUSPB).However, there is no report of the same patient's experience with both types of biopsy.To compare the patient reported experience in the same cohort of patients who underwent both TRUSPB and TTPB, using validated questionnaires. Material and methods: We retrospectively utilised the Patient Reported Outcome Methods (PROM) tool validated for TRUSPB and the International Index of Erectile Function (IIEF-5) questionnaire to collect longitudinal data at follow-up in the same cohort of patients who underwent both TTPB and TRUSPB between January 2015 and February 2016...
2018: Central European Journal of Urology
https://www.readbyqxmd.com/read/29730201/androgen-receptor-targeted-treatments-for-prostate-cancer-35-years-progress-with-antiandrogens
#18
REVIEW
E David Crawford, Paul F Schellhammer, David G McLeod, Judd W Moul, Celestia S Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A Eisenberger, Fernand Labrie
PURPOSE: Antiandrogens inhibit the androgen receptor (AR) and play an important role in the treatment of prostate cancer (PC). This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of PC. MATERIALS AND METHODS: We searched PubMed® for clinical trials with the search terms "antiandrogens" and "prostate cancer" combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with PC...
May 3, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29725805/oncological-safety-and-quality-of-life-in-men-undergoing-simultaneous-transurethral-resection-of-bladder-tumor-and-prostate-results-from-a-randomized-controlled-trial
#19
Marco Dellabella, Alessandro Branchi, Luca Gasparri, Redi Claudini, Daniele Castellani
PURPOSE: To assess oncological safety and quality of life (QL) of men undergoing simultaneous transurethral resection of bladder tumor (TURBT) and transurethral resection of the prostate (TURP) for symptomatic benign prostatic hyperplasia (BPH). METHODS: Ninety-five men with a new diagnosis of bladder cancer (BC) and symptomatic BPH were randomized to receive TURBT + tamsulosin (Group 1) or TURBT + TURP (Group 2). Inclusion criteria were age ≤ 75 years, first diagnosis of BC up to 4 cm, and prostate volume ≤ 80 ml...
May 3, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29724502/focal-therapy-for-prostate-cancer-a-more-vehement-view-of-the-approach-could-translate-into-real-benefits-for-our-patients
#20
EDITORIAL
Rafael Sanchez-Salas, Jean de la Rosette, Thomas J Polascik, Arie Carneiro, Arjun Sivaraman, Xavier Cathelineau, Jochen Walz
The literature on focal therapy is currently insufficient to recommend it as first-line treatment. We need information from both randomised controlled trials and prospective registries for every available energy. That said, important research is under way in this field, and the door should be kept open to an approach that has the potential to offer adequate cancer control with lower morbidity and better post-treatment quality of life in properly selected patients.
April 30, 2018: European Urology
keyword
keyword
100443
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"